Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.35 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.33 |
| ▸ | P4HB | P07237 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27712636 | 0.92 | S1PR5 (0.37) | S1PR5S1PR1 | |
| SCHEMBL4295816 | 0.89 | MEN1 (0.36) | S1PR5S1PR1MEN1POLBHTT | |
| SCHEMBL4287216 | 0.88 | S1PR1 (0.38) | S1PR5S1PR1MEN1HTTKMT2A | |
| SCHEMBL4290004 | 0.88 | MEN1 (0.41) | MEN1POLBHTTKMT2AL3MBTL1 | |
| SCHEMBL4295372 | 0.88 | MEN1 (0.41) | MEN1POLBHTTKMT2AL3MBTL1 | |
| SCHEMBL4287003 | 0.82 | MEN1 (0.43) | MEN1POLBHTTKMT2AL3MBTL1 | |
| SCHEMBL4296531 | 0.82 | S1PR1 (0.36) | S1PR5S1PR1MEN1HTTKMT2A | |
| SCHEMBL27692819 | 0.81 | OPRM1 (0.39) | S1PR5S1PR1 | |
| SCHEMBL4295325 | 0.78 | CNR2 (0.34) | S1PR5S1PR1POLBS1PR3S1PR4 | |
| SCHEMBL5796908 | 0.78 | RARB (0.36) | P4HBMEN1POLBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| WO-2006043149-A2 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIOPROJET (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | MGLL 1846/4885S1PR5 3/4885S1PR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.